Ignite Creation Date:
2024-06-16 @ 11:50 AM
Last Modification Date:
2024-10-26 @ 3:30 PM
Study NCT ID:
NCT06430450
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-05-28
First Post:
2024-05-21
Brief Title:
Determination of Salivary Soluble Urokinase Plasminogen Activator Receptor SuPAR Hypoxia-inducible Factor-1 Alpha HIF-1α E-cadherin Galectin 3 IL-4 IL-10 and TNF-α Levels in Individuals With Different Degrees of Periodontal Disease
Sponsor:
Karamanoğlu Mehmetbey University
Organization:
Karamanoğlu Mehmetbey University
Study Overview
Official Title:
Determination of Salivary Soluble Urokinase Plasminogen Activator Receptor SuPAR Hypoxia-inducible Factor-1 Alpha HIF-1α E-cadherin Galectin 3 IL-4 IL-10 and TNF-α Levels in Individuals With Different Degrees of Periodontal Disease
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of this clinical study is Comparatively comparing salivary Soluble Urokinase Plasminogen Activator Receptor SuPAR Hypoxia-inducible factor-1 alpha HIF-1α E-cadherin galectin 3 IL-4 IL-10 and TNF-α levels in individuals with different Periodontal Disease Degrees and to evaluate and analyze correlations with clinical parameters In our study saliva samples will be taken from a total of 80 systemically healthy volunteers 20 of patients are periodontal healthy 20 of patients have degree A periodontitis 20 of patients have degree B periodontitis and 20 of patients have degree C periodontitis along with the measurement of whole mouth clinical parameters Soluble Urokinase Plasminogen Activator Receptor SuPAR Hypoxia-inducible factor-1 alpha HIF-1α E-cadherin galectin 3 IL-4 IL-10 and TNF-α levels in the samples taken will be subjected to enzyme-related immunoassay It will be determined by ELISA Cytokine levels between different groups will then be interpreted as a result of statistical analysis Possible significant differences shed light on future studies with Soluble Urokinase Plasminogen Activator Receptor SuPAR Hypoxia-inducible factor-1 alpha HIF-1α E-cadherin galectin 3 IL-4 IL-10 and TNF-α These cytokines may help develop different diagnostic methods or treatment strategies in future periodontal treatments
Detailed Description:
The study included patients between the ages of 18 and 70 who applied to Karamanoğlu Mehmetbey University Ahmet Keleşoğlu Faculty of Dentistry Department of Periodontology were non-smokers had no systemic problems had not used antibiotics anti-inflammatory and systemic corticosteroid drugs in the last 3 months were not pregnant had not received periodontal treatment in the last 6 months and having at least 20 teeth in its mouth for grade A periodontitis group 20 individuals with a probing pocket depth of 5 mm or more in at least 2 teeth in each quadrant of the jaw attachment loss and radiological bone loss percentageage ratio 025 in the tooth with the most bone loss for grade B periodontitis group 20 individuals with a probing pocket depth of 5 mm or more in at least 2 teeth in each quadrant jaw attachment loss and a radiological bone loss percentageage ratio of 025-10 in the tooth with the most bone loss for grade C periodontitis group 20 individuals with a probing pocket depth of 5 mm or more in at least 2 teeth in each quadrant of the jaw attachment loss and radiological bone loss percentageage ratio 10 in the tooth with the most bone loss For the healthy group According to the evaluation made in 6 regions of each tooth including 20 individuals who show bleeding on probing in less than 20 of the area have a probing depth of less than 4 mm and have no attachment loss The healthy and periodontal disease group will consist of 80 patients in totalAnamnesis will be taken from individuals at the beginning of the interview and individuals who meet the specified criteria after the anamnesis will be included in the study After being informed about the study an informed consent form will be obtained from the individuals
After the anamnesis is taken clinical periodontal evaluations will be performed on individuals who are deemed to meet the inclusion criteria Clinically plaque index Sillness and Löe 1964 gingival index Löe and Sillness 1963 pocket depth and bleeding on probing indexAinamoBay 1975 will be recorded
Saliva samples will be taken from individuals divided into groups for biochemical examinations Saliva samples will be taken from each patient first frozen at -20ºC and than stored at -28ºC until the day of analysis Cytokine levels in the samples collected from the patients will be determined by the enzyme-related immune test Enzyme Linked-Immuno-Sorbent Assay ELISA
After the anamnesis is taken clinical periodontal evaluations will be performed on individuals who are deemed to meet the inclusion criteria Clinically plaque index Sillness and Löe 1964 gingival index Löe and Sillness 1963 pocket depth and bleeding on probing indexAinamoBay 1975 will be recorded
Saliva samples will be taken from individuals divided into groups for biochemical examinations Saliva samples will be taken from each patient first frozen at -20ºC and than stored at -28ºC until the day of analysis Cytokine levels in the samples collected from the patients will be determined by the enzyme-related immune test Enzyme Linked-Immuno-Sorbent Assay ELISA
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None